Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 390 results for lung cancer

  1. Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA777

  2. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published...

  3. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately increased...

  4. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  5. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer . Patient decision aid on intrabeam radiotherapy for treating early breast cancer

    for Intrabeam radiotherapy system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to...

  6. Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    7 May 2025

    Sections for TA1059

  7. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  8. Diabetic foot problems: prevention and management (NG19)

    This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

    NICE guideline
    Last updated
    11 October 2019
    View recommendations

    Sections for NG19

  9. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Discontinued Reference number: GID-TA11442

    Technology appraisal guidance
    Discontinued

  10. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at high risk Published March...

  11. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    23 July 2025
    View recommendations

    Sections for TA1079

  12. Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)

    Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

    Technology appraisal guidance
    Published
    25 February 2026
    View recommendations

    Sections for TA1136

  13. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  14. Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)

    Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.

    HealthTech guidance
    Published
    23 January 2024
    View recommendations

    Sections for HTG709

  15. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1071.

    Withdrawn guidance